QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)

NCT01782326 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

3362

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG: QVA149
DRUG: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)

Sponsor

Novartis Pharmaceuticals